Study to Evaluate Hemodynamic Response to to a Sublingual Dose of Glyceryl Trinitrate in Subjects Receiving TA-1790, Sildenafil Citrate, and Placebo

A Double-blind, Randomized, Crossover Evaluation of the Hemodynamic Response to Sublingual Glyceryl Trinitrate in Patients Receiving TA-1790, Sildenafil, and Placebo

The objective of this study is to evaluate the hemodynamic response to a sublingual dose of glyceryl trinitrate in subjects receiving oral TA-1790, sildenafil citrate, and placebo.

Inclusion Criteria:

• Provide written informed consent
• Willing to comply with all study requirements and clinic schedules
• Male between 30 to 60 years of age
• Non-smoker
• No history of alcohol abuse
• Normal screening laboratory values

Exclusion Criteria:

• Allergy or hypersensitive to PDE5 inhibitors
• Evidence of clinically significant disease
• Supine systolic/diastolic blood pressure level
• History of cardiovascular disease
• Previously participated in TA-1790 within the past 30 days